Walther, Carl P. http://orcid.org/0000-0003-0219-2870
Benoit, Julia S.
Gregg, L. Parker
Bansal, Nisha
Nambi, Vijay
Feldman, Harold I.
Shlipak, Michael G.
Navaneethan, Sankar D.
Appel, Lawrence J.
Chen, Jing
Go, Alan S.
Lash, James P.
Nelson, Robert G.
Rahman, Mahboob
Rao, Panduranga S.
Shah, Vallabh O.
Townsend, Raymond R.
Unruh, Mark L.
,
Article History
Received: 13 January 2022
Revised: 2 August 2022
Accepted: 3 August 2022
First Online: 17 August 2022
Competing interests
: Dr. Walther reports consulting fees from GlaxoSmithKline. Dr. Navaneethan reports personal fees from Bayer, personal fees from Boehringer-Ingelheim, personal fees from REATA, personal fees from Tricida, and grants from Keryx, outside the submitted work. Dr. Nambi has a provisional patent along with Roche and Baylor College of Medicine for use of biomarkers in prediction of heart failure risk and was the site PI for studies sponsored by Merck and Amgen. Dr. Shlipak has reported consulting fees from Cricket Health and Intercept Pharmaceuticals.